Linda Mileshkin

机构：The University of Melbourne, Peter MacCallum Cancer Centre, Mercy Hospital for Women, Australia New Zealand Gynaecological Oncology Group · ORCID：0000-0001-6826-6014

发表论文 563 篇 · 总被引 34150 次 · h-index 75

代表论文

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial (2025 · The Lancet Oncology · 被引 37)
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial (2026 · The Lancet · 被引 11)
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase I/IIa study (2025 · Gynecologic Oncology · 被引 2)
LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor (2025 · Annals of Oncology · 被引 2)
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial (2026 · International Journal of Gynecological Cancer · 被引 1)
ROSELLA (GOG3073, engotov72, APGOT-OV10): a phase 3 study of relacorilant + nab-paclitaxel in patients with platinum-resistant ovarian cancer (2026 · International Journal of Gynecological Cancer · 被引 1)